1-(5-isoquinolinesulfonyl)-2-methylpiperazine has been researched along with Disease Models, Animal in 172 studies
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine: A specific protein kinase C inhibitor, which inhibits superoxide release from human neutrophils (PMN) stimulated with phorbol myristate acetate or synthetic diacylglycerol.
1-(5-isoquinolinesulfonyl)-2-methylpiperazine : A member of the class of N-sulfonylpiperazines that is 2-methylpiperazine substituted at position 1 by a 5-isoquinolinesulfonyl group.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The current study was dedicated to investigating the vascular protective potential of Fasudil, a ROCK inhibitor, on an experimentally induced unilateral critical limb ischemia (CLI) model in mice and demonstrated the possible underlying mechanisms." | 8.12 | Fasudil, a ROCK inhibitor, preserves limb integrity in a mouse model of unilateral critical limb ischemia: Possible interplay of inflammatory and angiogenic signaling pathways. ( El-Waseif, AG; Elshaer, SL; Nader, MA; Salem, HA, 2022) |
| "This study aims to study the effect of Rho kinase inhibitor fasudil on the expression endothelin-1 (ET-1) and nitric oxide (NO) in rats with hypoxic pulmonary hypertension (HPH)." | 7.91 | Effect of Rho kinase inhibitor fasudil on the expression ET-1 and NO in rats with hypoxic pulmonary hypertension. ( Hong, Z; Li, JX; Li, SY; Sun, XZ; Tian, XY, 2019) |
| "To investigate whether there exists a cardio-protective effect of Fasudil, a selective Rho kinase (ROCK) inhibitor, in an experimental murine model of acute viral myocarditis." | 7.88 | Fasudil exerts a cardio-protective effect on mice with coxsackievirus B3-induced acute viral myocarditis. ( Chen, Q; Dai, K; Kuver, A; Li, J; Lian, H; Liao, W; Ni, H; Tai, S; Wang, Y; Yu, Y; Zheng, C, 2018) |
| "In this study, we tested the hypothesis that fasudil, a Rho kinase inhibitor, would protect against contrast-induced acute kidney injury (CI-AKI) in a mouse model and attempted to elucidate the mechanism involved." | 7.88 | Rho Kinase Inhibitor, Fasudil, Attenuates Contrast-induced Acute Kidney Injury. ( Miao, D; Wang, Y; Yang, Z; Zhang, D; Zhang, H, 2018) |
| " This study aims to investigate the protective effects of fasudil, a Rho-kinase inhibitor, on pressure overload induced heart failure in rats." | 7.88 | Fasudil alleviates pressure overload-induced heart failure by activating Nrf2-mediated antioxidant responses. ( Guan, P; Liang, Y; Wang, N, 2018) |
| "Fasudil, a Rho-kinase inhibitor, is a promising neuroprotectant against ischemic stroke; however, its low bioavailability is an obstacle to be overcome." | 7.83 | Neuroprotection against cerebral ischemia/reperfusion injury by intravenous administration of liposomal fasudil. ( Asai, T; Fukuta, T; Kikuchi, T; Koide, H; Namba, M; Oku, N; Sato, A; Shimizu, K; Yanagida, Y, 2016) |
| "Early CIMT promotes motor recovery after acute ischemic stroke when it is administered with fasudil pharmacotherapy, but not without it." | 7.83 | Combination of early constraint-induced movement therapy and fasudil enhances motor recovery after ischemic stroke in rats. ( Bonney, E; Chen, YH; Huang, FZ; Liu, BQ; Liu, YH; Wang, HX; Zhao, Y, 2016) |
| " This study was performed to determine the efficacy of ROCK inhibitor fasudil in blocking the development of hyperoxia-induced lung injury and fibrosis in neonatal rats." | 7.81 | Fasudil, an inhibitor of Rho-associated coiled-coil kinase, attenuates hyperoxia-induced pulmonary fibrosis in neonatal rats. ( Dang, HX; Fang, F; Li, J; Ning, W; Qi, XJ; Xu, F, 2015) |
| "To investigate the effects and mechanisms of fasudil hydrochloride (fasudil) on and in alkali burn-induced corneal neovascularization (CNV) in mice." | 7.81 | Fasudil hydrochloride, a potent ROCK inhibitor, inhibits corneal neovascularization after alkali burns in mice. ( Chen, RX; He, H; Li, P; Lin, LM; Pi, RB; Zeng, P; Zhou, SY, 2015) |
| "To investigate whether right ventricular hypertrophy in hypoxic pulmonary hypertension (HPH) rats could be prevented by treatment with Rho kinase inhibitor fasudil." | 7.81 | Effect of fasudil on hypoxic pulmonary hypertension and right ventricular hypertrophy in rats. ( Li, SY; Sun, XZ; Tian, XY; Wu, QQ, 2015) |
| " Monocrotaline (MCT)-induced and chronic hypoxia-induced PH models of rats were established, and the haemodynamic and pathomorphologic results of three different doses of fasudil (10 mg/kg, 30 mg/kg, and 75 mg/kg per day) were subsequently compared with those of bosentan (30 mg/kg per day)." | 7.80 | Fasudil reversed MCT-induced and chronic hypoxia-induced pulmonary hypertension by attenuating oxidative stress and inhibiting the expression of Trx1 and HIF-1α. ( Chen, S; Dong, K; Li, Z; Liu, M; Wang, Y; Zhang, B; Zheng, L; Zheng, W, 2014) |
| " To determine if a ROCK mechanism is involved in simvastatin-induced neuroprotection following embolic strokes, we used pharmacological intervention with the ROCK inhibitor, fasudil." | 7.76 | Simvastatin improves clinical scores in a rabbit multiple infarct ischemic stroke model: synergism with a ROCK inhibitor but not the thrombolytic tissue plasminogen activator. ( Han, MK; Lapchak, PA, 2010) |
| "In this article, the potential analgesic effects of Fasudil in a range of preclinical pain models were assessed." | 7.76 | Characterization of Fasudil in preclinical models of pain. ( Boyce-Rustay, JM; Chu, KL; Honore, P; McGaraughty, S; Simler, GH; Vasudevan, A; Wensink, EJ, 2010) |
| " Here, we used the model of hypoxia/reoxygenation (H/R) injury to explore the possibility whether Fasudil, a ROCK inhibitor in clinical application for subarachnoid hemorrhage and stroke, mobilizes adult neural stem cells in vivo." | 7.76 | Fasudil, a Rho kinase inhibitor, drives mobilization of adult neural stem cells after hypoxia/reoxygenation injury in mice. ( Ding, J; Li, QY; Lu, CZ; Sun, CH; Wang, X; Xiao, BG; Yu, JZ, 2010) |
| "Current antipsychotics used to treat schizophrenia have associated problems, including serious side effects and treatment resistance." | 5.72 | Antipsychotic-like effects of fasudil, a Rho-kinase inhibitor, in a pharmacologic animal model of schizophrenia. ( Kaibuchi, K; Liao, J; Liu, Y; Miyagawa, Y; Mizoguchi, H; Nagai, T; Ozaki, N; Sawahata, M; Sobue, A; Takase, S; Tanaka, R; Yamada, K, 2022) |
| " The aim of this study was to evaluate the anti-MPD activity of a clinically safe drug, Fasudil, identified in an in vitro kinase inhibitor as an inhibitor of proliferation of DKO mouse hematopoietic stem/progenitor cells (HSPCs)." | 5.43 | Fasudil, a clinically safe ROCK inhibitor, decreases disease burden in a Cbl/Cbl-b deficiency-driven murine model of myeloproliferative disorders. ( An, W; Band, H; Band, V; Feng, D; Mohapatra, BC; Nadeau, S; Storck, MA; William, BM, 2016) |
| "Renal fibrosis is the major cause of chronic kidney disease, and the Rho/Rho-associated coiled-coil kinase (ROCK) signaling cascade is involved in the renal fibrotic processes." | 5.42 | Inhibitory effects of fasudil on renal interstitial fibrosis induced by unilateral ureteral obstruction. ( Baba, I; Egi, Y; Kakimoto, T; Suzuki, K; Utsumi, H, 2015) |
| "Treatment with fasudil (30 mg kg(-1) day(-1)) was given intraperitoneally for 7, 14 or 21 days until mice underwent hemodynamic measurements." | 5.39 | Long-term treatment with fasudil improves bleomycin-induced pulmonary fibrosis and pulmonary hypertension via inhibition of Smad2/3 phosphorylation. ( Batteux, F; Bei, Y; Chen, W; Dinh-Xuan, AT; Duong-Quy, S; Hua-Huy, T; Nguyen, VH; Nicco, C, 2013) |
| "Moreover, fasudil slowed disease progression, increased survival time and reduced motor neuron loss, in SOD1(G93A) mice." | 5.39 | Fasudil, a rho kinase inhibitor, limits motor neuron loss in experimental models of amyotrophic lateral sclerosis. ( Hara, H; Kawasaki, K; Kimura, M; Nagahara, Y; Seto, M; Shimazawa, M; Takata, M; Tanaka, H; Tanaka, K; Tsuruma, K, 2013) |
| "The pathology of cerebral malaria is considered to be primarily immunological." | 5.36 | Modulation of cerebral malaria by fasudil and other immune-modifying compounds. ( Ginsburg, H; Golenser, J; Hunt, N; McQuillan, JA; Waknine-Grinberg, JH, 2010) |
| " A selective Rho-kinase inhibitor, fasudil, has recently been shown to improve renal damage resulting from hypertensive glomerulosclerosis, unilateral ureteral obstruction (for interstitial renal fibrosis) and subtotal nephrectomy." | 4.83 | Molecular mechanisms and therapeutic strategies of chronic renal injury: role of rho-kinase in the development of renal injury. ( Hayashi, K; Homma, K; Kanda, T; Saruta, T; Sugano, N; Wakino, S, 2006) |
| "The current study was dedicated to investigating the vascular protective potential of Fasudil, a ROCK inhibitor, on an experimentally induced unilateral critical limb ischemia (CLI) model in mice and demonstrated the possible underlying mechanisms." | 4.12 | Fasudil, a ROCK inhibitor, preserves limb integrity in a mouse model of unilateral critical limb ischemia: Possible interplay of inflammatory and angiogenic signaling pathways. ( El-Waseif, AG; Elshaer, SL; Nader, MA; Salem, HA, 2022) |
| " We have previously demonstrated that fasudil, a Rho/ROCK inhibitor, has antioxidant, anti-inflammatory and anti-apoptotic effects in contrast-induced acute kidney injury model." | 4.02 | Alleviation of the doxorubicin-induced nephrotoxicity by fasudil in vivo and in vitro. ( Xiang, C; Yan, Y; Zhang, D, 2021) |
| "In conclusion, fasudil treatment decreased necrosis of perforator flaps possibly by affecting the Akt/eNOS/NO pathway, attenuating apoptosis and activating autophagy." | 3.96 | Pharmacological Effects of Fasudil on Flap Survival in a Rodent Model. ( Gao, W; Ji, E; Pan, Z; Wang, J; Wang, L, 2020) |
| "This study aims to study the effect of Rho kinase inhibitor fasudil on the expression endothelin-1 (ET-1) and nitric oxide (NO) in rats with hypoxic pulmonary hypertension (HPH)." | 3.91 | Effect of Rho kinase inhibitor fasudil on the expression ET-1 and NO in rats with hypoxic pulmonary hypertension. ( Hong, Z; Li, JX; Li, SY; Sun, XZ; Tian, XY, 2019) |
| "To investigate whether there exists a cardio-protective effect of Fasudil, a selective Rho kinase (ROCK) inhibitor, in an experimental murine model of acute viral myocarditis." | 3.88 | Fasudil exerts a cardio-protective effect on mice with coxsackievirus B3-induced acute viral myocarditis. ( Chen, Q; Dai, K; Kuver, A; Li, J; Lian, H; Liao, W; Ni, H; Tai, S; Wang, Y; Yu, Y; Zheng, C, 2018) |
| "In this study, we tested the hypothesis that fasudil, a Rho kinase inhibitor, would protect against contrast-induced acute kidney injury (CI-AKI) in a mouse model and attempted to elucidate the mechanism involved." | 3.88 | Rho Kinase Inhibitor, Fasudil, Attenuates Contrast-induced Acute Kidney Injury. ( Miao, D; Wang, Y; Yang, Z; Zhang, D; Zhang, H, 2018) |
| "To investigate the effect of fasudil, a Rho-kinase inhibitor, on chronic ischemia-related bladder dysfunction." | 3.88 | Protective Effect of a Rho-kinase Inhibitor on Bladder Dysfunction in a Rat Model of Chronic Bladder Ischemia. ( Aikawa, K; Akaihata, H; Haga, N; Hata, J; Ishibashi, K; Koguchi, T; Kojima, Y; Kushida, N; Matsuoka, K; Nomiya, M, 2018) |
| " This study aims to investigate the protective effects of fasudil, a Rho-kinase inhibitor, on pressure overload induced heart failure in rats." | 3.88 | Fasudil alleviates pressure overload-induced heart failure by activating Nrf2-mediated antioxidant responses. ( Guan, P; Liang, Y; Wang, N, 2018) |
| "Early CIMT promotes motor recovery after acute ischemic stroke when it is administered with fasudil pharmacotherapy, but not without it." | 3.83 | Combination of early constraint-induced movement therapy and fasudil enhances motor recovery after ischemic stroke in rats. ( Bonney, E; Chen, YH; Huang, FZ; Liu, BQ; Liu, YH; Wang, HX; Zhao, Y, 2016) |
| "Fasudil, a Rho-kinase inhibitor, is a promising neuroprotectant against ischemic stroke; however, its low bioavailability is an obstacle to be overcome." | 3.83 | Neuroprotection against cerebral ischemia/reperfusion injury by intravenous administration of liposomal fasudil. ( Asai, T; Fukuta, T; Kikuchi, T; Koide, H; Namba, M; Oku, N; Sato, A; Shimizu, K; Yanagida, Y, 2016) |
| "To investigate the effects and mechanisms of fasudil hydrochloride (fasudil) on and in alkali burn-induced corneal neovascularization (CNV) in mice." | 3.81 | Fasudil hydrochloride, a potent ROCK inhibitor, inhibits corneal neovascularization after alkali burns in mice. ( Chen, RX; He, H; Li, P; Lin, LM; Pi, RB; Zeng, P; Zhou, SY, 2015) |
| " This study was performed to determine the efficacy of ROCK inhibitor fasudil in blocking the development of hyperoxia-induced lung injury and fibrosis in neonatal rats." | 3.81 | Fasudil, an inhibitor of Rho-associated coiled-coil kinase, attenuates hyperoxia-induced pulmonary fibrosis in neonatal rats. ( Dang, HX; Fang, F; Li, J; Ning, W; Qi, XJ; Xu, F, 2015) |
| " We develop and utilize a glyoxylate induced mouse model of kidney calcium oxalate crystal deposition for studying the pharmacological effects of fasudil, a Rho associated protein kinase (ROCK) specific inhibitor, on the kidney injury and fibrosis caused by calcium oxalate crystallization and deposition." | 3.81 | Fasudil prevents calcium oxalate crystal deposit and renal fibrogenesis in glyoxylate-induced nephrolithic mice. ( Chen, W; Ding, J; Guo, Z; Hu, H; Jia, M; Yin, J, 2015) |
| "To investigate whether right ventricular hypertrophy in hypoxic pulmonary hypertension (HPH) rats could be prevented by treatment with Rho kinase inhibitor fasudil." | 3.81 | Effect of fasudil on hypoxic pulmonary hypertension and right ventricular hypertrophy in rats. ( Li, SY; Sun, XZ; Tian, XY; Wu, QQ, 2015) |
| " Monocrotaline (MCT)-induced and chronic hypoxia-induced PH models of rats were established, and the haemodynamic and pathomorphologic results of three different doses of fasudil (10 mg/kg, 30 mg/kg, and 75 mg/kg per day) were subsequently compared with those of bosentan (30 mg/kg per day)." | 3.80 | Fasudil reversed MCT-induced and chronic hypoxia-induced pulmonary hypertension by attenuating oxidative stress and inhibiting the expression of Trx1 and HIF-1α. ( Chen, S; Dong, K; Li, Z; Liu, M; Wang, Y; Zhang, B; Zheng, L; Zheng, W, 2014) |
| "The effects of such regimens were investigated on hemodynamics, right ventricle hypertrophy, PDGF and ROCK in experimental monocrotaline (MCT)-induced pulmonary hypertension." | 3.80 | Concurrent rho-kinase and tyrosine kinase platelet-derived growth factor inhibition in experimental pulmonary hypertension. ( Jasińska-Stroschein, M; Orszulak-Michalak, D; Owczarek, J; Plichta, P, 2014) |
| " To determine if a ROCK mechanism is involved in simvastatin-induced neuroprotection following embolic strokes, we used pharmacological intervention with the ROCK inhibitor, fasudil." | 3.76 | Simvastatin improves clinical scores in a rabbit multiple infarct ischemic stroke model: synergism with a ROCK inhibitor but not the thrombolytic tissue plasminogen activator. ( Han, MK; Lapchak, PA, 2010) |
| " Here, we used the model of hypoxia/reoxygenation (H/R) injury to explore the possibility whether Fasudil, a ROCK inhibitor in clinical application for subarachnoid hemorrhage and stroke, mobilizes adult neural stem cells in vivo." | 3.76 | Fasudil, a Rho kinase inhibitor, drives mobilization of adult neural stem cells after hypoxia/reoxygenation injury in mice. ( Ding, J; Li, QY; Lu, CZ; Sun, CH; Wang, X; Xiao, BG; Yu, JZ, 2010) |
| "In this article, the potential analgesic effects of Fasudil in a range of preclinical pain models were assessed." | 3.76 | Characterization of Fasudil in preclinical models of pain. ( Boyce-Rustay, JM; Chu, KL; Honore, P; McGaraughty, S; Simler, GH; Vasudevan, A; Wensink, EJ, 2010) |
| "We investigated the neuroprotective effects of fasudil's active metabolite, hydroxyfasudil, a Rho-kinase inhibitor, in a rat stroke model in which endothelial damage and subsequent thrombotic occlusion were selectively induced in perforating arteries." | 3.76 | Amelioration of endothelial damage/dysfunction is a possible mechanism for the neuroprotective effects of Rho-kinase inhibitors against ischemic brain damage. ( Asano, T; Hitomi, A; Ikegaki, I; Iwasaki, M; Kawasaki, K; Mohri, M; Nakazono, O; Satoh, S, 2010) |
| " Therefore, we determined the effects of two Rho-kinase inhibitors, Y-27632 and fasudil, on seizures induced by pentylenetetrazole (PTZ) or maximal electroconvulsive shock (MES)." | 3.74 | Antiepileptic effects of two Rho-kinase inhibitors, Y-27632 and fasudil, in mice. ( Büyükafşar, K; Inan, S, 2008) |
| "The present study was undertaken to investigate the effect of fasudil, a specific Rho-kinase inhibitor, in pathological cardiac hypertrophy induced by partial abdominal aortic constriction (PAAC) for 4 weeks in comparison with physiological cardiac hypertrophy caused by chronic swimming training (CST) for 8 weeks in rats." | 3.73 | Differential role of rho-kinase in pathological and physiological cardiac hypertrophy in rats. ( Balakumar, P; Singh, M, 2006) |
| "We studied the antiischemic properties of fasudil, a Rho-kinase inhibitor, in conscious rabbits with coronary vasospasm induced by vasopressin and endothelin." | 3.71 | Antiischemic properties of fasudil in experimental models of vasospastic angina. ( Asano, T; Ikegaki, I; Sato, S; Shimokawa, H, 2001) |
| "To date, the pharmacologic approach to cerebral vasospasm and ischemia has been hampered in part by an inability to attain sufficiently high concentrations of drugs in the cerebrospinal fluid (CSF)." | 2.42 | [Development of drug delivery system for intrathecal administration and its therapeutic effect on cerebral vasospasm and ischemia]. ( Ishida, T, 2004) |
| "Current antipsychotics used to treat schizophrenia have associated problems, including serious side effects and treatment resistance." | 1.72 | Antipsychotic-like effects of fasudil, a Rho-kinase inhibitor, in a pharmacologic animal model of schizophrenia. ( Kaibuchi, K; Liao, J; Liu, Y; Miyagawa, Y; Mizoguchi, H; Nagai, T; Ozaki, N; Sawahata, M; Sobue, A; Takase, S; Tanaka, R; Yamada, K, 2022) |
| "Ursolic acid (UA) is a traditional Chinese medicine with anti-fibrotic effects, but the molecular mechanism underlying these effects is still unclear." | 1.56 | Ursolic acid reverses liver fibrosis by inhibiting interactive NOX4/ROS and RhoA/ROCK1 signalling pathways. ( Huang, C; Liu, C; Luo, F; Luo, Q; Wan, S; Zhu, X, 2020) |
| "Fasudil treatment notably ameliorated ADR-induced cardiac damage, restored heart function, suppressed cell apoptosis and senescence, ameliorated redox imbalance, and DNA damage." | 1.56 | Rho Kinase Inhibition by Fasudil Attenuates Adriamycin-Induced Chronic Heart Injury. ( Miao, D; Xiang, C; Yan, Y; Yang, Z; Zhang, D, 2020) |
| "The cuprizone (CPZ)-induced demyelination is widely used to investigate the demyelination/remyelination." | 1.51 | Hydroxyfasudil alleviates demyelination through the inhibition of MOG antibody and microglia activation in cuprizone mouse model. ( Li, YH; Ma, CG; Miao, Q; Song, LJ; Sui, RX; Wang, J; Wang, Q; Xiao, BG; Yu, JZ, 2019) |
| "Fasudil is a Rho-kinase inhibitor that has shown therapeutic benefits in brain disorders." | 1.48 | Fasudil hydrochloride ameliorates memory deficits in rat model of streptozotocin-induced Alzheimer's disease: Involvement of PI3-kinase, eNOS and NFκB. ( Bansal, N; Kumar, M, 2018) |
| "Fasudil co-treatment normalized the high-glucose-induced upregulation of these mediators." | 1.48 | Rho-Associated Protein Kinase-1 Mediates the Regulation of Inflammatory Markers in Diabetic Retina and in Retinal Müller Cells. ( Abu El-Asrar, AM; Ahmad, A; Alam, K; AlSharif, HM; Mohammad, G; Siddiquei, MM, 2018) |
| "The high mortality of pancreatic cancer demands that new therapeutic avenues be developed." | 1.48 | Rho Kinase Inhibition by AT13148 Blocks Pancreatic Ductal Adenocarcinoma Invasion and Tumor Growth. ( Cutiongco, MF; Gadegaard, N; Jagiełło, A; Kamphorst, JJ; Mackay, G; McGarry, L; Michalopoulou, E; Munro, J; Olson, MF; Pajic, M; Rath, N; Sumpton, D; Timpson, P; Unbekandt, M; Vennin, C, 2018) |
| "Cystitis is defined as an inflammation of the bladder caused by a bacterial infection, and it can be dangerous and painful when it spreads through the internal organs." | 1.48 | A novel therapeutics agent: antioxidant effects of hydroxylfasudil on rat kidney and liver tissues in a protamine sulphate-induced cystitis rat model; preliminary results. ( Akin, Y; Bozkurt, A; Budak, H; Can, S; Cankaya, M; Coban, TA; Erol, HS; Halici, MB; Mercantepe, T; Ozbey, I, 2018) |
| "Fasudil treatment improved cognitive function and central nervous system (CNS) injury, and decreased SC susceptibility in rats." | 1.46 | Effect of fasudil on cognitive function following status convulsion in rats. ( Cheng, L; Han, W; He, R; Jiang, L; Song, X; Tang, X, 2017) |
| "Our study aimed firstly to describe pulmonary inflammation and fibrosis induced by HOCl in mice, and secondly to determine whether fasudil, a selective inhibitor of ROCK, could prevent lung and skin fibroses in HOCl-injected mice." | 1.43 | RhoA/Rho-kinase activation promotes lung fibrosis in an animal model of systemic sclerosis. ( Batteux, F; Bei, Y; Chéreau, C; Dinh-Xuan, AT; Duong-Quy, S; Hua-Huy, T; Le-Dong, NN; Nicco, C; Tiev, KP, 2016) |
| "Fasudil treatment significantly reduced α-Syn aggregation in vitro in a H4 cell culture model as well as in a cell-free assay." | 1.43 | Fasudil attenuates aggregation of α-synuclein in models of Parkinson's disease. ( Bähr, M; Becker, S; Dambeck, V; Eckermann, K; Fonseca-Ornelas, L; Koch, JC; Lingor, P; Lopes da Fonseca, T; Outeiro, TF; Tatenhorst, L; Tönges, L; Walle, H; Zweckstetter, M, 2016) |
| "To investigate lung injuries, the immunohistochemistry of lung tissue, immune cell infiltrations, cytokine productions in bronchoalveolar lavage (BAL) fluid, and seurm inflammatory cytokines were evaluated." | 1.43 | Fasudil, an inhibitor of Rho-associated coiled-coil kinase, improves cognitive impairments induced by smoke exposure. ( Chunhua, M; Kun, H; Xueyang, D; Zhanqiang, M, 2016) |
| " The aim of this study was to evaluate the anti-MPD activity of a clinically safe drug, Fasudil, identified in an in vitro kinase inhibitor as an inhibitor of proliferation of DKO mouse hematopoietic stem/progenitor cells (HSPCs)." | 1.43 | Fasudil, a clinically safe ROCK inhibitor, decreases disease burden in a Cbl/Cbl-b deficiency-driven murine model of myeloproliferative disorders. ( An, W; Band, H; Band, V; Feng, D; Mohapatra, BC; Nadeau, S; Storck, MA; William, BM, 2016) |
| "Renal fibrosis is the major cause of chronic kidney disease, and the Rho/Rho-associated coiled-coil kinase (ROCK) signaling cascade is involved in the renal fibrotic processes." | 1.42 | Inhibitory effects of fasudil on renal interstitial fibrosis induced by unilateral ureteral obstruction. ( Baba, I; Egi, Y; Kakimoto, T; Suzuki, K; Utsumi, H, 2015) |
| "Fasudil‑treated mice developed a significantly smaller intima‑media thickness compared with the untreated mice." | 1.42 | Fasudil, a Rho‑kinase inhibitor, prevents intima‑media thickening in a partially ligated carotid artery mouse model: Effects of fasudil in flow‑induced vascular remodeling. ( Gao, F; Li, Q; Li, W; Li, Y; Shen, C; Zhang, T; Zhang, X, 2015) |
| "The phenotypic manifestations of cerebral cavernous malformation disease caused by rare PDCD10 mutations have not been systematically examined, and a mechanistic link to Rho kinase-mediated hyperpermeability, a potential therapeutic target, has not been established." | 1.42 | Exceptional aggressiveness of cerebral cavernous malformation disease associated with PDCD10 mutations. ( Akers, AL; Austin, C; Awad, IA; De Souza, JM; Gallione, CJ; Gunel, M; Lee, C; Marchuk, DA; McDonald, DA; Mikati, AG; Min, W; Rebeiz, T; Rorrer, A; Shenkar, R; Shi, C; Stockton, RA; Zhang, L, 2015) |
| "Treatment with fasudil (30 mg kg(-1) day(-1)) was given intraperitoneally for 7, 14 or 21 days until mice underwent hemodynamic measurements." | 1.39 | Long-term treatment with fasudil improves bleomycin-induced pulmonary fibrosis and pulmonary hypertension via inhibition of Smad2/3 phosphorylation. ( Batteux, F; Bei, Y; Chen, W; Dinh-Xuan, AT; Duong-Quy, S; Hua-Huy, T; Nguyen, VH; Nicco, C, 2013) |
| "Moreover, fasudil slowed disease progression, increased survival time and reduced motor neuron loss, in SOD1(G93A) mice." | 1.39 | Fasudil, a rho kinase inhibitor, limits motor neuron loss in experimental models of amyotrophic lateral sclerosis. ( Hara, H; Kawasaki, K; Kimura, M; Nagahara, Y; Seto, M; Shimazawa, M; Takata, M; Tanaka, H; Tanaka, K; Tsuruma, K, 2013) |
| "Fasudil treatment significantly improved survival and decreased proteinuria, particularly when treatment was started at 18 weeks." | 1.38 | Administration of fasudil, a ROCK inhibitor, attenuates disease in lupus-prone NZB/W F1 female mice. ( Bhagat, G; Biswas, PS; Gupta, S; Pernis, AB; Song, L; Stirzaker, RA, 2012) |
| "Chronic cerebral vasospasm was produced using a two-hemorrhage canine model." | 1.38 | Antivasospastic effects of hydroxyfasudil, a Rho-kinase inhibitor, after subarachnoid hemorrhage. ( Asano, T; Hitomi, A; Ikegaki, I; Kawasaki, K; Satoh, S; Shibuya, M; Takayasu, M; Yano, K, 2012) |
| "Fasudil was administered by oral gavage from post-natal day 3 to 21 at a concentration of 30 mg/kg twice daily." | 1.38 | Fasudil improves survival and promotes skeletal muscle development in a mouse model of spinal muscular atrophy. ( Anderson, CL; Bowerman, M; Boyer, JG; Kothary, R; Murray, LM, 2012) |
| "The treatment with fasudil significantly decreased 1) histological damage; 2) motor recovery; 3) nuclear factor-κB (NF-κB) expression; 4) ROK activity; 5) inflammasome activation (caspase-1 and NOD-like receptor family, pyrin domain-containing 3 expression); 6) production of proinflammatory cytokine such as tumor necrosis factor and interleukin-1β (IL-1β); 7) neutrophil infiltration; 8) nitrotyrosine and poly-ADP-ribose formation; 9) glial fibrillary acidic protein expression; 10) apoptosis (terminal deoxynucleotidyl transferase dUTP nick-end labeling staining, FAS ligand expression, and Bax and Bcl-2 expression); and 11) mitogen-activated protein kinase activation (phospho-extracellular signal-regulated kinase and phospho-c-Jun NH(2)-terminal kinase expression)." | 1.38 | Effect of fasudil, a selective inhibitor of Rho kinase activity, in the secondary injury associated with the experimental model of spinal cord trauma. ( Cuzzocrea, S; Esposito, E; Impellizzeri, D; Mazzon, E; Paterniti, I, 2012) |
| "Treatment with valsartan and fasudil prevented the development of vasoconstriction, improved the carotid blood flow and normalized the hypersensitivity to serotonin." | 1.37 | Involvement of Rho-kinase in collar-induced vasoconstriction and vascular hypersensitivity to serotonin in rat carotid. ( Guan, Q; Pang, X; Sun, D; Xie, L; Zeng, D; Zhang, H, 2011) |
| "Treatment with fasudil normalized these molecular and histologic alterations, and restored erectile function." | 1.37 | Chronic treatment with an oral rho-kinase inhibitor restores erectile function by suppressing corporal apoptosis in diabetic rats. ( Kim, SW; Li, WJ; Paick, JS; Park, K, 2011) |
| "Fasudil treatment was associated with a significant reduction in secretion of IFN-γ; by contrast, secretion of IL-4 was almost the same in the fasudil- and PBS-treated groups." | 1.37 | Preventive and therapeutic effects of the selective Rho-kinase inhibitor fasudil on experimental autoimmune neuritis. ( Kawamura, N; Kira, J; Matsushita, T; Minohara, M; Piao, H; Pineda, AA; Shimokawa, H; Sun, X; Yamasaki, R, 2011) |
| "2." | 1.37 | Rho kinase inhibition by fasudil exerts antioxidant effects in hypercholesterolemic rats. ( Cao, G; Chu, L; Ji, E; Li, G; Ma, Z; Zhang, J, 2011) |
| "Dermal scarring and scar contracture result in restriction of movement." | 1.37 | Wound contraction is attenuated by fasudil inhibition of Rho-associated kinase. ( Bergeron, A; Bond, JE; Kokosis, G; Levinson, H; Ren, L; Selim, MA, 2011) |
| "Fasudil treated SJL/J mice showed increased body weight, but decreased grip strength, horizontal activity, and soleus muscle force, compared to untreated SJL/J controls." | 1.36 | Characterization of dysferlin deficient SJL/J mice to assess preclinical drug efficacy: fasudil exacerbates muscle disease phenotype. ( Gordish-Dressman, H; Hoffman, EP; Knoblach, SM; Nagaraju, K; Rayavarapu, S; Van der Meulen, JH, 2010) |
| "Groups 2-4 (n=15 each) were subjected to cerebral aneurysm induction procedures plus 1% NaCl in the drinking water." | 1.36 | Fasudil, a Rho-kinase inhibitor, attenuates induction and progression of cerebral aneurysms: experimental study in rats using vascular corrosion casts. ( Eldawoody, H; Kimura, N; Nakayama, T; Saito, A; Shimizu, H; Takahashi, A; Tominaga, T, 2010) |
| "The pathology of cerebral malaria is considered to be primarily immunological." | 1.36 | Modulation of cerebral malaria by fasudil and other immune-modifying compounds. ( Ginsburg, H; Golenser, J; Hunt, N; McQuillan, JA; Waknine-Grinberg, JH, 2010) |
| "These results show in secondary biliary cirrhosis that (1) Rho-kinase activation with resultant eNOS down-regulation is substantially involved in the pathogenesis of portal hypertension and (2) Rho-kinase might interact with Akt and subsequently inhibit the binding of Akt to eNOS." | 1.35 | Defective endothelial nitric oxide synthase signaling is mediated by rho-kinase activation in rats with secondary biliary cirrhosis. ( Anegawa, G; Hashizume, M; Kawanaka, H; Kinjo, N; Konishi, K; Maehara, Y; Shimokawa, H; Taketomi, A; Yamaguchi, S; Yoshida, D, 2008) |
| "Cerebral ischemia was induced in rats by injecting 150 mug of sodium laurate into the left internal carotid artery on day 1." | 1.35 | Wide therapeutic time window for Rho-kinase inhibition therapy in ischemic brain damage in a rat cerebral thrombosis model. ( Asano, T; Hitomi, A; Ikegaki, I; Satoh, S; Seto, M; Toshima, Y, 2008) |
| "Fasudil treatment significantly ameliorated those DHF-related myocardial changes." | 1.35 | Long-term inhibition of Rho-kinase ameliorates diastolic heart failure in hypertensive rats. ( Fukui, S; Fukumoto, Y; Kagaya, Y; Nawata, J; Saji, K; Shimokawa, H; Shinozaki, T; Suzuki, J; Tawara, S, 2008) |
| "post-treatment with fasudil, which possesses the inhibitory effect of several protein kinases including PKC and Rho kinase." | 1.34 | [Effects of fasudil on neuropathic pain-like state in mice]. ( Inoue, T; Miyoshi, K; Nagumo, Y; Narita, M; Okutsu, D; Shiokawa, M; Suzuki, M; Suzuki, T; Yamaguchi, T, 2007) |
| "The treatment with fasudil partly but significantly ameliorated the development of pelvic atherosclerosis and plasma level of von Willebrand factor." | 1.33 | Chronic administration of an oral Rho kinase inhibitor prevents the development of vasculogenic erectile dysfunction in a rat model. ( Kim, SW; Paick, JS; Park, K; Rhu, KS, 2006) |
| "Delayed cerebral vasospasm after subarachnoid hemorrhage (SAH) may be due, in part, to altered regulation of arterial smooth muscle contraction." | 1.33 | Activation of Rho-associated kinase during augmented contraction of the basilar artery to serotonin after subarachnoid hemorrhage. ( Faraci, FM; Heistad, DD; Watanabe, Y, 2005) |
| " Higher baseline IOP and repeated dosing were associated with greater IOP reduction." | 1.32 | Effects of topical H-7 on outflow facility, intraocular pressure, and corneal thickness in monkeys. ( Kaufman, PL; Podos, SM; Tian, B; Wang, RF, 2004) |
| "Treatment with fasudil (1 and 10 mg/kg, n=15 each) resulted in a significant improvement in neurological deficits." | 1.31 | A new model of cerebral microthrombosis in rats and the neuroprotective effect of a Rho-kinase inhibitor. ( Asano, T; Ikegaki, I; Satoh, S; Toshima, Y, 2000) |
| "Gram-negative sepsis/septic shock in the newborn continues to be a major medical problem, causing high mortality." | 1.29 | Lipopolysaccharide alters suckling rat liver glycogenolysis. ( Goto, M; Goto, MP; Hurley, RM; Picken, M; Zeller, WP, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.58) | 18.7374 |
| 1990's | 4 (2.33) | 18.2507 |
| 2000's | 40 (23.26) | 29.6817 |
| 2010's | 110 (63.95) | 24.3611 |
| 2020's | 17 (9.88) | 2.80 |
| Authors | Studies |
|---|---|
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 2 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Chen, D | 1 |
| Yuan, T | 1 |
| Chen, Y | 2 |
| Zhang, H | 4 |
| Niu, Z | 1 |
| Fang, L | 1 |
| Du, G | 1 |
| Yan, H | 1 |
| Yan, Y | 3 |
| Gao, Y | 1 |
| Zhang, N | 1 |
| Kumar, G | 1 |
| Fang, Q | 1 |
| Li, Z | 2 |
| Li, J | 4 |
| Zhang, Y | 4 |
| Song, L | 3 |
| Wang, J | 6 |
| Sun, J | 1 |
| Zhang, HT | 1 |
| Ma, CG | 9 |
| Takase, S | 1 |
| Liao, J | 1 |
| Liu, Y | 1 |
| Tanaka, R | 1 |
| Miyagawa, Y | 1 |
| Sawahata, M | 1 |
| Sobue, A | 1 |
| Mizoguchi, H | 1 |
| Nagai, T | 1 |
| Kaibuchi, K | 2 |
| Ozaki, N | 1 |
| Yamada, K | 1 |
| El-Waseif, AG | 1 |
| Nader, MA | 1 |
| Salem, HA | 1 |
| Elshaer, SL | 1 |
| Gómez, GI | 1 |
| Velarde, V | 1 |
| Sáez, JC | 1 |
| Xiang, C | 2 |
| Yang, Z | 2 |
| Miao, D | 2 |
| Zhang, D | 4 |
| Wan, S | 1 |
| Luo, F | 1 |
| Huang, C | 1 |
| Liu, C | 1 |
| Luo, Q | 1 |
| Zhu, X | 1 |
| Ji, E | 2 |
| Wang, L | 1 |
| Pan, Z | 1 |
| Gao, W | 1 |
| Streets, AJ | 1 |
| Prosseda, PP | 1 |
| Ong, AC | 1 |
| Detter, MR | 1 |
| Shenkar, R | 3 |
| Benavides, CR | 1 |
| Neilson, CA | 1 |
| Moore, T | 2 |
| Lightle, R | 2 |
| Hobson, N | 1 |
| Shen, L | 1 |
| Cao, Y | 2 |
| Girard, R | 2 |
| Griffin, E | 1 |
| Gallione, CJ | 2 |
| Awad, IA | 3 |
| Marchuk, DA | 3 |
| Lopez-Lopez, A | 1 |
| Labandeira, CM | 1 |
| Labandeira-Garcia, JL | 1 |
| Muñoz, A | 1 |
| Guo, MF | 3 |
| Zhang, HY | 1 |
| Zhang, PJ | 1 |
| Liu, XQ | 1 |
| Song, LJ | 4 |
| Wei, WY | 1 |
| Wang, YY | 1 |
| Mu, BT | 1 |
| Chai, Z | 3 |
| Yu, JZ | 7 |
| Martin Lorenzo, S | 1 |
| Nalesso, V | 1 |
| Chevalier, C | 1 |
| Birling, MC | 1 |
| Herault, Y | 2 |
| Zhang, J | 3 |
| Wang, W | 2 |
| Wang, H | 3 |
| Liu, J | 1 |
| Zhang, Z | 1 |
| Ding, ZB | 1 |
| Han, QX | 1 |
| Wang, Q | 3 |
| Chu, GG | 1 |
| Xiao, BG | 9 |
| Li, XY | 1 |
| Wei, W | 1 |
| Wang, Y | 5 |
| Gu, Q | 1 |
| Liu, X | 1 |
| Guo, M | 1 |
| Yu, J | 2 |
| Ma, C | 2 |
| Jasińska-Stroschein, M | 2 |
| Oszajca, K | 1 |
| Świtlik, W | 1 |
| Ruchwa, J | 1 |
| Orszulak-Michalak, D | 2 |
| He, R | 1 |
| Han, W | 1 |
| Song, X | 2 |
| Tang, X | 1 |
| Cheng, L | 1 |
| Jiang, L | 1 |
| Kangawa, Y | 1 |
| Yoshida, T | 1 |
| Yonezawa, Y | 1 |
| Maruyama, K | 1 |
| Hayashi, SM | 1 |
| Shibutani, M | 1 |
| Chan, SL | 1 |
| Cipolla, MJ | 1 |
| Fan, R | 1 |
| Enkhjargal, B | 1 |
| Camara, R | 1 |
| Yan, F | 1 |
| Gong, L | 1 |
| Tang, J | 1 |
| Zhang, JH | 1 |
| Wu, S | 1 |
| Rothschild, PR | 1 |
| Salah, S | 1 |
| Berdugo, M | 1 |
| Gélizé, E | 1 |
| Delaunay, K | 1 |
| Naud, MC | 1 |
| Klein, C | 1 |
| Moulin, A | 1 |
| Savoldelli, M | 1 |
| Bergin, C | 1 |
| Jeanny, JC | 1 |
| Jonet, L | 1 |
| Arsenijevic, Y | 1 |
| Behar-Cohen, F | 1 |
| Crisanti, P | 1 |
| Li, L | 2 |
| Sun, H | 1 |
| Ding, J | 5 |
| Niu, C | 1 |
| Su, M | 1 |
| Zhang, L | 3 |
| Li, Y | 4 |
| Wang, C | 2 |
| Gamper, N | 1 |
| Du, X | 1 |
| Hensel, N | 1 |
| Baskal, S | 1 |
| Walter, LM | 1 |
| Brinkmann, H | 1 |
| Gernert, M | 1 |
| Claus, P | 1 |
| Akaihata, H | 1 |
| Nomiya, M | 1 |
| Matsuoka, K | 1 |
| Koguchi, T | 1 |
| Hata, J | 1 |
| Haga, N | 1 |
| Kushida, N | 1 |
| Ishibashi, K | 2 |
| Aikawa, K | 1 |
| Kojima, Y | 1 |
| Guan, P | 1 |
| Liang, Y | 1 |
| Wang, N | 1 |
| Bozkurt, A | 1 |
| Budak, H | 1 |
| Erol, HS | 1 |
| Can, S | 1 |
| Mercantepe, T | 1 |
| Akin, Y | 1 |
| Ozbey, I | 1 |
| Cankaya, M | 1 |
| Halici, MB | 1 |
| Coban, TA | 1 |
| Sun, XZ | 2 |
| Li, SY | 2 |
| Tian, XY | 2 |
| Hong, Z | 1 |
| Li, JX | 1 |
| Rath, N | 1 |
| Munro, J | 1 |
| Cutiongco, MF | 1 |
| Jagiełło, A | 1 |
| Gadegaard, N | 1 |
| McGarry, L | 1 |
| Unbekandt, M | 1 |
| Michalopoulou, E | 1 |
| Kamphorst, JJ | 1 |
| Sumpton, D | 1 |
| Mackay, G | 1 |
| Vennin, C | 1 |
| Pajic, M | 1 |
| Timpson, P | 1 |
| Olson, MF | 1 |
| Mohammad, G | 1 |
| AlSharif, HM | 1 |
| Siddiquei, MM | 1 |
| Ahmad, A | 1 |
| Alam, K | 1 |
| Abu El-Asrar, AM | 1 |
| Hanson, SFL | 1 |
| Terry, MH | 2 |
| Moretta, DT | 1 |
| Power, GG | 2 |
| Wilson, SM | 2 |
| Alam, F | 1 |
| Ahsan, F | 3 |
| Blood, AB | 2 |
| Giri, PC | 1 |
| Yang, Q | 1 |
| Liu, F | 1 |
| Ma, W | 1 |
| Hu, H | 2 |
| Ran, C | 1 |
| Li, F | 1 |
| Pan, Q | 1 |
| Kumar, M | 1 |
| Bansal, N | 1 |
| Elliott, C | 1 |
| Rojo, AI | 1 |
| Ribe, E | 1 |
| Broadstock, M | 1 |
| Xia, W | 1 |
| Morin, P | 1 |
| Semenov, M | 1 |
| Baillie, G | 1 |
| Cuadrado, A | 1 |
| Al-Shawi, R | 1 |
| Ballard, CG | 1 |
| Simons, P | 1 |
| Killick, R | 1 |
| Dai, K | 1 |
| Tai, S | 1 |
| Ni, H | 1 |
| Lian, H | 1 |
| Yu, Y | 1 |
| Liao, W | 1 |
| Zheng, C | 1 |
| Chen, Q | 1 |
| Kuver, A | 1 |
| Yan, X | 1 |
| Jiao, K | 1 |
| Sui, RX | 1 |
| Miao, Q | 1 |
| Li, YH | 4 |
| Song, J | 1 |
| Xi, JY | 3 |
| Yu, WB | 2 |
| Yan, C | 1 |
| Luo, SS | 1 |
| Zhou, L | 2 |
| Zhu, WH | 1 |
| Lu, JH | 1 |
| Dong, Q | 1 |
| Zhao, CB | 1 |
| Brockmann, C | 1 |
| Corkhill, C | 1 |
| Jaroslawska, E | 1 |
| Dege, S | 1 |
| Brockmann, T | 1 |
| Kociok, N | 1 |
| Joussen, AM | 1 |
| Keshavarz, A | 1 |
| Alobaida, A | 1 |
| McMurtry, IF | 3 |
| Nozik-Grayck, E | 1 |
| Stenmark, KR | 1 |
| Greathouse, KM | 1 |
| Henderson, BW | 1 |
| Gentry, EG | 1 |
| Herskowitz, JH | 1 |
| Li, M | 2 |
| Yasumura, D | 1 |
| Ma, AA | 1 |
| Matthes, MT | 1 |
| Yang, H | 1 |
| Nielson, G | 1 |
| Huang, Y | 1 |
| Szoka, FC | 1 |
| Lavail, MM | 1 |
| Diamond, MI | 1 |
| Jiang, ZH | 1 |
| Zhang, TT | 1 |
| Zhang, JF | 1 |
| Matoba, K | 2 |
| Kawanami, D | 2 |
| Okada, R | 1 |
| Tsukamoto, M | 1 |
| Kinoshita, J | 1 |
| Ito, T | 2 |
| Ishizawa, S | 2 |
| Kanazawa, Y | 2 |
| Yokota, T | 2 |
| Murai, N | 1 |
| Matsufuji, S | 1 |
| Takahashi-Fujigasaki, J | 2 |
| Utsunomiya, K | 2 |
| Chen, X | 1 |
| Takata, M | 1 |
| Tanaka, H | 1 |
| Kimura, M | 1 |
| Nagahara, Y | 1 |
| Tanaka, K | 1 |
| Kawasaki, K | 4 |
| Seto, M | 3 |
| Tsuruma, K | 2 |
| Shimazawa, M | 2 |
| Hara, H | 2 |
| Yagita, Y | 1 |
| Kitagawa, K | 1 |
| Oyama, N | 1 |
| Yukami, T | 1 |
| Watanabe, A | 3 |
| Sasaki, T | 1 |
| Mochizuki, H | 1 |
| Peng, W | 1 |
| Zhou, Q | 1 |
| Ao, X | 1 |
| Tang, R | 1 |
| Xiao, Z | 1 |
| Jiang, H | 1 |
| Guan, RJ | 1 |
| Wang, HY | 1 |
| Bei, Y | 2 |
| Hua-Huy, T | 2 |
| Duong-Quy, S | 2 |
| Nguyen, VH | 1 |
| Chen, W | 2 |
| Nicco, C | 2 |
| Batteux, F | 2 |
| Dinh-Xuan, AT | 2 |
| Tönges, L | 4 |
| Günther, R | 1 |
| Suhr, M | 1 |
| Jansen, J | 1 |
| Balck, A | 1 |
| Saal, KA | 3 |
| Barski, E | 1 |
| Nientied, T | 1 |
| Götz, AA | 1 |
| Koch, JC | 4 |
| Mueller, BK | 1 |
| Weishaupt, JH | 2 |
| Sereda, MW | 1 |
| Hanisch, UK | 1 |
| Bähr, M | 4 |
| Lingor, P | 4 |
| Owczarek, J | 1 |
| Plichta, P | 1 |
| Meng, J | 2 |
| Liu, CY | 1 |
| Feng, L | 3 |
| Yang, WF | 1 |
| Li, JL | 1 |
| Feng, QJ | 1 |
| Liu, M | 1 |
| Zheng, L | 1 |
| Zheng, W | 1 |
| Dong, K | 1 |
| Chen, S | 1 |
| Zhang, B | 1 |
| Tatenhorst, L | 3 |
| Szegő, ÉM | 2 |
| Huang, L | 2 |
| Zhao, LB | 1 |
| Yu, ZY | 1 |
| He, XJ | 1 |
| Ma, LP | 1 |
| Li, N | 1 |
| Guo, LJ | 2 |
| Feng, WY | 1 |
| Shi, C | 2 |
| Rebeiz, T | 1 |
| Stockton, RA | 1 |
| McDonald, DA | 2 |
| Mikati, AG | 1 |
| Austin, C | 2 |
| Akers, AL | 1 |
| Rorrer, A | 2 |
| Gunel, M | 1 |
| Min, W | 1 |
| De Souza, JM | 1 |
| Lee, C | 1 |
| Lee, HS | 1 |
| Kim, KS | 1 |
| Lim, HS | 1 |
| Choi, M | 1 |
| Kim, HK | 1 |
| Ahn, HY | 1 |
| Shin, JC | 1 |
| Joe, YA | 1 |
| Shang, H | 1 |
| Chen, JK | 1 |
| Tao, HQ | 1 |
| Zhang, CL | 1 |
| Gupta, N | 1 |
| Ibrahim, HM | 1 |
| Liu, YH | 1 |
| Zhao, Y | 2 |
| Huang, FZ | 1 |
| Chen, YH | 1 |
| Wang, HX | 2 |
| Bonney, E | 1 |
| Liu, BQ | 1 |
| Nozaki, Y | 1 |
| Kinoshita, K | 1 |
| Hino, S | 1 |
| Yano, T | 1 |
| Niki, K | 1 |
| Hirooka, Y | 1 |
| Kishimoto, K | 1 |
| Funauchi, M | 1 |
| Matsumura, I | 1 |
| Jia, M | 1 |
| Yin, J | 1 |
| Guo, Z | 1 |
| Zhao, YF | 2 |
| Zhang, Q | 3 |
| Wang, B | 1 |
| Ding, YM | 1 |
| Wang, CT | 1 |
| Wang, WX | 1 |
| Xi, J | 1 |
| Xiao, B | 2 |
| Zeng, P | 1 |
| Pi, RB | 1 |
| Li, P | 1 |
| Chen, RX | 1 |
| Lin, LM | 1 |
| He, H | 1 |
| Zhou, SY | 1 |
| William, BM | 1 |
| An, W | 1 |
| Feng, D | 1 |
| Nadeau, S | 1 |
| Mohapatra, BC | 1 |
| Storck, MA | 1 |
| Band, V | 1 |
| Band, H | 1 |
| Xie, T | 1 |
| Luo, G | 1 |
| Wang, X | 3 |
| Wu, M | 2 |
| Li, G | 2 |
| Zhang, X | 2 |
| Zhang, T | 1 |
| Gao, F | 1 |
| Li, Q | 2 |
| Shen, C | 1 |
| Wu, QQ | 1 |
| Mera, C | 1 |
| Godoy, I | 1 |
| Ramírez, R | 1 |
| Moya, J | 1 |
| Ocaranza, MP | 2 |
| Jalil, JE | 2 |
| Baba, I | 1 |
| Egi, Y | 1 |
| Utsumi, H | 1 |
| Kakimoto, T | 1 |
| Suzuki, K | 1 |
| Zhang, YB | 1 |
| Guo, ZD | 1 |
| Li, MY | 1 |
| Fong, P | 1 |
| Zhang, JG | 1 |
| Zhang, CW | 1 |
| Gong, KR | 1 |
| Yang, MF | 1 |
| Niu, JZ | 1 |
| Ji, XM | 1 |
| Lv, GW | 1 |
| Qi, XJ | 1 |
| Ning, W | 1 |
| Xu, F | 1 |
| Dang, HX | 1 |
| Fang, F | 1 |
| Chen, C | 1 |
| Zhang, HF | 1 |
| Lin, L | 1 |
| Luan, X | 1 |
| Jing, X | 1 |
| Le-Dong, NN | 1 |
| Tiev, KP | 1 |
| Chéreau, C | 1 |
| Eckermann, K | 1 |
| Dambeck, V | 1 |
| Fonseca-Ornelas, L | 1 |
| Walle, H | 1 |
| Lopes da Fonseca, T | 1 |
| Becker, S | 1 |
| Outeiro, TF | 1 |
| Zweckstetter, M | 1 |
| Fukuta, T | 1 |
| Asai, T | 1 |
| Sato, A | 1 |
| Namba, M | 1 |
| Yanagida, Y | 1 |
| Kikuchi, T | 1 |
| Koide, H | 1 |
| Shimizu, K | 1 |
| Oku, N | 1 |
| Fierro, C | 1 |
| Novoa, U | 1 |
| González, V | 1 |
| Meziane, H | 1 |
| Khelfaoui, M | 1 |
| Morello, N | 1 |
| Hiba, B | 1 |
| Calcagno, E | 1 |
| Reibel-Foisset, S | 1 |
| Selloum, M | 1 |
| Chelly, J | 1 |
| Humeau, Y | 1 |
| Riet, F | 1 |
| Zanni, G | 1 |
| Bienvenu, T | 1 |
| Giustetto, M | 1 |
| Billuart, P | 1 |
| Yu, JW | 1 |
| Liu, JC | 1 |
| Yan, YP | 1 |
| Zhang, GX | 1 |
| Ohata, K | 1 |
| Chen-Yoshikawa, TF | 1 |
| Menju, T | 1 |
| Miyamoto, E | 1 |
| Tanaka, S | 1 |
| Takahashi, M | 1 |
| Motoyama, H | 1 |
| Hijiya, K | 1 |
| Aoyama, A | 1 |
| Date, H | 1 |
| Xueyang, D | 1 |
| Zhanqiang, M | 1 |
| Chunhua, M | 1 |
| Kun, H | 1 |
| Zeineddine, HA | 1 |
| Gallione, C | 1 |
| Pytel, P | 1 |
| Liao, JK | 1 |
| García-Rojo, G | 1 |
| Fresno, C | 1 |
| Vilches, N | 1 |
| Díaz-Véliz, G | 1 |
| Mora, S | 1 |
| Aguayo, F | 1 |
| Pacheco, A | 1 |
| Parra-Fiedler, N | 1 |
| Parra, CS | 1 |
| Rojas, PS | 1 |
| Tejos, M | 1 |
| Aliaga, E | 1 |
| Fiedler, JL | 1 |
| Rao, J | 1 |
| Ye, Z | 1 |
| Tang, H | 1 |
| Peng, H | 1 |
| Lai, W | 1 |
| Huang, W | 1 |
| Lou, T | 1 |
| Inan, S | 1 |
| Büyükafşar, K | 1 |
| Cheng, C | 1 |
| Webber, CA | 1 |
| Xu, Y | 1 |
| Martinez, JA | 1 |
| Liu, WQ | 1 |
| McDonald, D | 1 |
| Guo, GF | 1 |
| Nguyen, MD | 1 |
| Zochodne, DW | 1 |
| Huang, XJ | 1 |
| He, W | 1 |
| Jia, JT | 1 |
| Fu, G | 1 |
| Fukunaga, T | 1 |
| Ikesugi, K | 1 |
| Nishio, M | 1 |
| Sugimoto, M | 1 |
| Sasoh, M | 1 |
| Hidaka, H | 2 |
| Uji, Y | 1 |
| Kroll, J | 1 |
| Epting, D | 1 |
| Kern, K | 1 |
| Dietz, CT | 1 |
| Feng, Y | 1 |
| Hammes, HP | 1 |
| Wieland, T | 1 |
| Augustin, HG | 1 |
| Ying, Z | 1 |
| Yue, P | 1 |
| Xu, X | 1 |
| Zhong, M | 1 |
| Sun, Q | 1 |
| Mikolaj, M | 1 |
| Wang, A | 1 |
| Brook, RD | 1 |
| Chen, LC | 1 |
| Rajagopalan, S | 1 |
| Ytrebo, LM | 1 |
| Wu, DJ | 1 |
| Xu, JZ | 1 |
| Wu, YJ | 1 |
| Jean-Charles, L | 1 |
| Gao, PJ | 1 |
| Zhu, DL | 1 |
| Satoh, S | 5 |
| Hitomi, A | 3 |
| Ikegaki, I | 8 |
| Nakazono, O | 1 |
| Iwasaki, M | 1 |
| Mohri, M | 1 |
| Asano, T | 7 |
| Masago, T | 1 |
| Watanabe, T | 1 |
| Saito, M | 1 |
| Kinoshita, Y | 1 |
| Sato, K | 1 |
| Miyagawa, I | 1 |
| Ziino, AJ | 1 |
| Ivanovska, J | 2 |
| Belcastro, R | 1 |
| Kantores, C | 2 |
| Xu, EZ | 2 |
| Lau, M | 1 |
| McNamara, PJ | 2 |
| Tanswell, AK | 1 |
| Jankov, RP | 2 |
| Li, QY | 1 |
| Sun, CH | 2 |
| Lu, CZ | 2 |
| Xie, L | 1 |
| Zeng, D | 1 |
| Sun, D | 1 |
| Pang, X | 1 |
| Guan, Q | 1 |
| Eldawoody, H | 1 |
| Shimizu, H | 1 |
| Kimura, N | 1 |
| Saito, A | 1 |
| Nakayama, T | 1 |
| Takahashi, A | 1 |
| Tominaga, T | 1 |
| Sun, YF | 1 |
| Waknine-Grinberg, JH | 1 |
| McQuillan, JA | 1 |
| Hunt, N | 1 |
| Ginsburg, H | 1 |
| Golenser, J | 1 |
| Baba, H | 1 |
| Tanoue, Y | 1 |
| Maeda, T | 1 |
| Kobayashi, M | 1 |
| Oda, S | 1 |
| Tominaga, R | 1 |
| Li, WJ | 1 |
| Park, K | 2 |
| Paick, JS | 2 |
| Kim, SW | 2 |
| Boyce-Rustay, JM | 1 |
| Simler, GH | 1 |
| McGaraughty, S | 1 |
| Chu, KL | 1 |
| Wensink, EJ | 1 |
| Vasudevan, A | 1 |
| Honore, P | 1 |
| Lapchak, PA | 1 |
| Han, MK | 1 |
| de Frutos, S | 1 |
| Caldwell, E | 1 |
| Nitta, CH | 1 |
| Kanagy, NL | 1 |
| Walker, MK | 1 |
| Gonzalez Bosc, LV | 1 |
| Xie, LN | 1 |
| Zeng, DY | 1 |
| Zhang, HS | 1 |
| Sun, DM | 1 |
| Pang, XF | 1 |
| Guan, QG | 1 |
| Rayavarapu, S | 1 |
| Van der Meulen, JH | 1 |
| Gordish-Dressman, H | 1 |
| Hoffman, EP | 1 |
| Nagaraju, K | 1 |
| Knoblach, SM | 1 |
| Engelberts, D | 1 |
| Kavanagh, BP | 1 |
| Ray, P | 1 |
| Wright, J | 1 |
| Adam, J | 1 |
| Boucharens, S | 1 |
| Black, D | 1 |
| Brown, AR | 1 |
| Epemolu, O | 1 |
| Fletcher, D | 1 |
| Huggett, M | 1 |
| Jones, P | 1 |
| Laats, S | 1 |
| Lyons, A | 1 |
| de Man, J | 1 |
| Morphy, R | 1 |
| Sherborne, B | 1 |
| Sherry, L | 1 |
| Straten, Nv | 1 |
| Westwood, P | 1 |
| York, M | 1 |
| Washida, N | 1 |
| Wakino, S | 3 |
| Tonozuka, Y | 1 |
| Homma, K | 2 |
| Tokuyama, H | 1 |
| Hara, Y | 1 |
| Hasegawa, K | 1 |
| Minakuchi, H | 1 |
| Fujimura, K | 1 |
| Hosoya, K | 1 |
| Hayashi, K | 3 |
| Itoh, H | 1 |
| Pineda, AA | 1 |
| Minohara, M | 2 |
| Kawamura, N | 1 |
| Matsushita, T | 1 |
| Yamasaki, R | 1 |
| Sun, X | 2 |
| Piao, H | 2 |
| Shimokawa, H | 10 |
| Kira, J | 2 |
| Nagayoshi, M | 1 |
| Tada, Y | 1 |
| West, J | 1 |
| Ochiai, E | 1 |
| Toyotome, T | 1 |
| Tanabe, N | 1 |
| Takiguchi, Y | 1 |
| Shigeta, A | 1 |
| Yasuda, T | 1 |
| Shibuya, K | 1 |
| Kamei, K | 1 |
| Tatsumi, K | 1 |
| Gong, K | 1 |
| Zhou, W | 1 |
| Shao, G | 1 |
| Li, S | 1 |
| Lin, Q | 1 |
| Ma, Z | 1 |
| Cao, G | 1 |
| Chu, L | 1 |
| Ding, RY | 1 |
| Zhao, DM | 1 |
| Zhang, ZD | 1 |
| Guo, RX | 1 |
| Ma, XC | 1 |
| Bond, JE | 1 |
| Kokosis, G | 1 |
| Ren, L | 1 |
| Selim, MA | 1 |
| Bergeron, A | 1 |
| Levinson, H | 1 |
| Zhang, M | 1 |
| Shan, H | 1 |
| Gu, Z | 1 |
| Wang, D | 1 |
| Wang, T | 1 |
| Wang, Z | 1 |
| Tao, L | 1 |
| Hou, Y | 1 |
| Yang, QD | 1 |
| Du, XP | 1 |
| Yuan, M | 1 |
| Zhou, ZW | 1 |
| Takayasu, M | 1 |
| Yano, K | 2 |
| Shibuya, M | 2 |
| Stirzaker, RA | 1 |
| Biswas, PS | 1 |
| Gupta, S | 1 |
| Bhagat, G | 1 |
| Pernis, AB | 1 |
| Bowerman, M | 1 |
| Murray, LM | 1 |
| Boyer, JG | 1 |
| Anderson, CL | 1 |
| Kothary, R | 1 |
| Raja, SG | 1 |
| Ishiguro, M | 1 |
| Suzuki, Y | 2 |
| Ishizuka, F | 1 |
| Mishiro, K | 1 |
| Egashira, Y | 1 |
| Yoshimura, S | 1 |
| Iwama, T | 1 |
| Impellizzeri, D | 1 |
| Mazzon, E | 1 |
| Paterniti, I | 1 |
| Esposito, E | 1 |
| Cuzzocrea, S | 1 |
| Frank, T | 1 |
| Merritt, TA | 1 |
| Papamatheakis, DG | 1 |
| Blood, Q | 1 |
| Ross, JM | 1 |
| Longo, LD | 1 |
| Takabayashi, N | 1 |
| Tajima, N | 1 |
| Satoh, Si | 1 |
| Toshima, Y | 3 |
| Kandabashi, T | 1 |
| Miyata, K | 1 |
| Kunihiro, I | 1 |
| Eto, Y | 1 |
| Morishige, K | 1 |
| Matsumoto, Y | 1 |
| Obara, K | 1 |
| Nakayama, K | 1 |
| Takahashi, S | 1 |
| Takeshita, A | 1 |
| Kitaoka, Y | 2 |
| Kumai, T | 1 |
| Lam, TT | 1 |
| Kuribayashi, K | 1 |
| Isenoumi, K | 1 |
| Munemasa, Y | 1 |
| Motoki, M | 1 |
| Kobayashi, S | 1 |
| Ueno, S | 1 |
| Gabelt, BT | 1 |
| Hennes, EA | 1 |
| Seeman, JL | 1 |
| Tian, B | 2 |
| Kaufman, PL | 2 |
| Ishida, T | 1 |
| Wang, RF | 1 |
| Podos, SM | 1 |
| Nagaoka, T | 1 |
| Fagan, KA | 1 |
| Gebb, SA | 1 |
| Morris, KG | 2 |
| Suzuki, T | 2 |
| Oka, M | 2 |
| Watanabe, Y | 1 |
| Faraci, FM | 1 |
| Heistad, DD | 1 |
| Nishikimi, T | 2 |
| Matsuoka, H | 1 |
| Kanda, T | 2 |
| Sugano, N | 1 |
| Saruta, T | 1 |
| Nishio, Y | 1 |
| Koda, M | 1 |
| Kitajo, K | 1 |
| Hata, K | 2 |
| Taniguchi, J | 1 |
| Moriya, H | 2 |
| Fujitani, M | 1 |
| Kubo, T | 2 |
| Yamashita, T | 2 |
| Thorlacius, K | 1 |
| Slotta, JE | 1 |
| Laschke, MW | 1 |
| Menger, MD | 1 |
| Jeppsson, B | 1 |
| Thorlacius, H | 1 |
| Balakumar, P | 1 |
| Singh, M | 1 |
| Kikuchi, H | 1 |
| Ishizu, T | 1 |
| Tanaka, M | 1 |
| Osoegawa, M | 1 |
| Ohyagi, Y | 1 |
| Rhu, KS | 1 |
| Abe, K | 1 |
| Tawara, S | 3 |
| Oi, K | 1 |
| Hizume, T | 1 |
| Uwatoku, T | 1 |
| Fukumoto, Y | 3 |
| Madura, T | 1 |
| Tanag, M | 1 |
| Matsuda, K | 1 |
| Tomita, K | 1 |
| Hosokawa, K | 1 |
| Homma, N | 1 |
| Taraseviciene-Stewart, L | 1 |
| Kraskauskas, D | 1 |
| Burns, N | 1 |
| Voelkel, NF | 1 |
| He, Z | 1 |
| Guo, L | 1 |
| Ohtori, S | 1 |
| Inoue, G | 1 |
| Takahashi, K | 1 |
| Shiokawa, M | 1 |
| Yamaguchi, T | 1 |
| Narita, M | 1 |
| Okutsu, D | 1 |
| Nagumo, Y | 1 |
| Miyoshi, K | 1 |
| Suzuki, M | 1 |
| Inoue, T | 1 |
| Anegawa, G | 1 |
| Kawanaka, H | 1 |
| Yoshida, D | 1 |
| Konishi, K | 1 |
| Yamaguchi, S | 1 |
| Kinjo, N | 1 |
| Taketomi, A | 1 |
| Hashizume, M | 1 |
| Maehara, Y | 1 |
| Fukui, S | 1 |
| Suzuki, J | 1 |
| Saji, K | 1 |
| Nawata, J | 1 |
| Shinozaki, T | 1 |
| Kagaya, Y | 1 |
| Shibata, I | 1 |
| Yoshitomi, O | 1 |
| Use, T | 1 |
| Ureshino, H | 1 |
| Cho, S | 1 |
| Maekawa, T | 1 |
| Hara, T | 1 |
| Sumikawa, K | 1 |
| Kawamura, S | 1 |
| Yasui, N | 1 |
| Shirasawa, M | 1 |
| Fukasawa, H | 1 |
| Goto, M | 1 |
| Zeller, WP | 1 |
| Picken, M | 1 |
| Goto, MP | 1 |
| Hurley, RM | 1 |
| Ikeda, S | 1 |
| Fukuzaki, A | 1 |
| Kaneto, H | 1 |
| Ishidoya, S | 1 |
| Orikasa, S | 1 |
| Nakamura, K | 1 |
| Shinozuka, K | 1 |
| Kunitomo, M | 1 |
| Sato, S | 1 |
| Harada, T | 1 |
| Sugita, K | 1 |
| Struhar, D | 1 |
| Harbeck, RJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pilot Study of Telmisartan (Micardis) For the Prevention of Acute Graft vs. Host Disease Post Allogeneic Hematopoietic Stem Cell Transplantation[NCT02338232] | 32 participants (Actual) | Interventional | 2015-07-07 | Terminated (stopped due to Lack of Accrual) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Disease Models, Animal
| Article | Year |
|---|---|
Effects of fasudil on pulmonary hypertension in clinical practice.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Disease Models, Animal; Drug Synergism; Huma | 2017 |
Evaluation of clinical efficacy of fasudil for the treatment of pulmonary arterial hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cardiovascular System; Disease Models, Anima | 2012 |
[Development of drug delivery system for intrathecal administration and its therapeutic effect on cerebral vasospasm and ischemia].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain Ischemia; Delayed-Action Preparations; | 2004 |
Molecular mechanisms and therapeutic strategies of chronic renal injury: renoprotective effect of rho-kinase inhibitor in hypertensive glomerulosclerosis.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blood Pressure; Collagen; Disease Models, An | 2006 |
Molecular mechanisms and therapeutic strategies of chronic renal injury: role of rho-kinase in the development of renal injury.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Angiotensin II; Animals; Cyclin-Dependent Kinase Inhi | 2006 |
Rho/Rho kinase as a potential target for the treatment of renal disease.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Animals; Disease Models, Animal; Enzyme Inhib | 2005 |
[Role of the Rho/Rho-kinase pathway in the development of hypertensive glomerulosclerosis: renoprotective effect of Rho-kinase inhibitor in hypertensive glomerulosclerosis and its molecular mechanism].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Disease Models, Animal; Glomerulosclerosis, | 2006 |
[Suppressive effect of protein kinase C inhibitors on tumor cell function via phosphorylation of p53 protein in mice].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Disease Models, Animal; Enzyme Inhibitors; H | 2000 |
164 other studies available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Disease Models, Animal
| Article | Year |
|---|---|
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
DL0805-1, a novel Rho-kinase inhibitor, attenuates lung injury and vasculopathy in a rat model of monocrotaline-induced pulmonary hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Bosentan; Disease Models, Animal; Hypertensi | 2022 |
Transcriptome analysis of fasudil treatment in the APPswe/PSEN1dE9 transgenic (APP/PS1) mice model of Alzheimer's disease.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Alzheimer Disease; Animals; Animals, Genetically Modi | 2022 |
Antipsychotic-like effects of fasudil, a Rho-kinase inhibitor, in a pharmacologic animal model of schizophrenia.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Antipsychotic Agents; Disease Models, Animal | 2022 |
Fasudil, a ROCK inhibitor, preserves limb integrity in a mouse model of unilateral critical limb ischemia: Possible interplay of inflammatory and angiogenic signaling pathways.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Antioxidants; Chronic Limb-Threatening Ische | 2022 |
Role of a RhoA/ROCK-Dependent Pathway on Renal Connexin43 Regulation in the Angiotensin II-Induced Renal Damage.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Angiotensin II; Animals; Connexin 43; Creatinine; Dis | 2019 |
Rho Kinase Inhibition by Fasudil Attenuates Adriamycin-Induced Chronic Heart Injury.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Antioxidants; Apoptosis; Biomarkers; Cardiot | 2020 |
Ursolic acid reverses liver fibrosis by inhibiting interactive NOX4/ROS and RhoA/ROCK1 signalling pathways.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Acetophenones; Animals; Carbon Tetrachloride; Disease | 2020 |
Pharmacological Effects of Fasudil on Flap Survival in a Rodent Model.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Apoptosis; Autophagy; Disease Models, Animal | 2020 |
Polycystin-1 regulates ARHGAP35-dependent centrosomal RhoA activation and ROCK signaling.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Actins; Animals; Cell Line; Centrosome; Cilia; Diseas | 2020 |
Novel Murine Models of Cerebral Cavernous Malformations.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Acute Disease; Animals; Apoptosis Regulatory Proteins | 2020 |
Rho kinase inhibitor fasudil reduces l-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Disease Models, Animal; Dyskinesia, Drug-Ind | 2020 |
Alleviation of the doxorubicin-induced nephrotoxicity by fasudil in vivo and in vitro.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Acute Kidney Injury; Animals; Apoptosis; Cells, Cultu | 2021 |
Fasudil reduces β-amyloid levels and neuronal apoptosis in APP/PS1 transgenic mice via inhibition of the Nogo-A/NgR/RhoA signaling axis.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Alzheimer Disease; Amyloid beta-Peptides; Animals; Ap | 2020 |
Targeting the RHOA pathway improves learning and memory in adult Kctd13 and 16p11.2 deletion mouse models.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Alleles; Animals; Autism Spectrum Disorder; Autistic | 2021 |
Fasudil protects retinal ganglion cells and promotes axonal regeneration.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Actin Depolymerizing Factors; Animals; Apoptosis; Axo | 2020 |
Fasudil enhances the phagocytosis of myelin debris and the expression of neurotrophic factors in cuprizone-induced demyelinating mice.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain-Derived Neurotrophic Factor; Cell Diff | 2021 |
Fasudil ameliorates cognitive deficits, oxidative stress and neuronal apoptosis via inhibiting ROCK/MAPK and activating Nrf2 signalling pathways in APP/PS1 mice.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Alzheimer Disease; Amyloid beta-Protein Precursor; An | 2021 |
Treatment with platelet-derived growth factor (PDGF) and rock inhibitors is related to declined nerve growth factor (NGF) signaling in an experimental model of rat pulmonary hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Disease Models, Animal; Enzyme-Linked Immuno | 2017 |
Effect of fasudil on cognitive function following status convulsion in rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; CA1 Region, Hippocampal; Cognition; Disease | 2017 |
Suppression of epithelial restitution using an inhibitor against Rho-associated coiled-coil containing protein kinase aggravates colitis through reduced epithelial expression of A-kinase anchor protein 13.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; A Kinase Anchor Proteins; Animals; Colitis; Dextran S | 2017 |
Treatment with low dose fasudil for acute ischemic stroke in chronic hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cerebrovascular Circulation; Chronic Disease | 2017 |
Critical role of EphA4 in early brain injury after subarachnoid hemorrhage in rat.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blood-Brain Barrier; Brain; Brain Edema; Bra | 2017 |
ROCK-1 mediates diabetes-induced retinal pigment epithelial and endothelial cell blebbing: Contribution to diabetic retinopathy.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aged; Animals; Biomarkers; Case-Control Studies; Cyto | 2017 |
Selective targeting of M-type potassium K
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Behavior, Animal; Depression; Disease Models | 2017 |
ERK and ROCK functionally interact in a signaling network that is compensationally upregulated in Spinal Muscular Atrophy.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Benzimidazoles; Cell Death; Cell Line; Cytop | 2017 |
Rho Kinase Inhibitor, Fasudil, Attenuates Contrast-induced Acute Kidney Injury.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Acute Kidney Injury; Animals; Apoptosis; Biomarkers; | 2018 |
Protective Effect of a Rho-kinase Inhibitor on Bladder Dysfunction in a Rat Model of Chronic Bladder Ischemia.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Chronic Disease; Disease Models, Animal; Isc | 2018 |
Fasudil alleviates pressure overload-induced heart failure by activating Nrf2-mediated antioxidant responses.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Antioxidants; Disease Models, Animal; Heart | 2018 |
A novel therapeutics agent: antioxidant effects of hydroxylfasudil on rat kidney and liver tissues in a protamine sulphate-induced cystitis rat model; preliminary results.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Antioxidants; Catalase; Cystitis; Disease Mo | 2018 |
Effect of Rho kinase inhibitor fasudil on the expression ET-1 and NO in rats with hypoxic pulmonary hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Disease Models, Animal; Endothelin-1; Hypert | 2019 |
Rho Kinase Inhibition by AT13148 Blocks Pancreatic Ductal Adenocarcinoma Invasion and Tumor Growth.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; 2-Hydroxyphenethylamine; Amides; Animals; Antineoplas | 2018 |
Rho-Associated Protein Kinase-1 Mediates the Regulation of Inflammatory Markers in Diabetic Retina and in Retinal Müller Cells.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cells, Cultured; Chemokine CCL2; Cytokines; | 2018 |
Inhaled Fasudil Lacks Pulmonary Selectivity in Thromboxane-Induced Acute Pulmonary Hypertension in Newborn Lambs.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Administration, Inhalation; Aerosols; Animals; Animal | 2018 |
A Novel Rabbit Model for Benign Biliary Stricture Formation and the Effects of Medication Infusions on Stricture Formation.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Antineoplastic Agents; Biliary Tract Disease | 2018 |
Fasudil hydrochloride ameliorates memory deficits in rat model of streptozotocin-induced Alzheimer's disease: Involvement of PI3-kinase, eNOS and NFκB.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Alzheimer Disease; Animals; Disease Models, Animal; E | 2018 |
A role for APP in Wnt signalling links synapse loss with β-amyloid production.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Alzheimer Disease; Amyloid beta-Protein Precursor; An | 2018 |
Fasudil exerts a cardio-protective effect on mice with coxsackievirus B3-induced acute viral myocarditis.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Anti-Inflammatory Agents; Antiviral Agents; | 2018 |
Shen'ge powder decreases the cardiomyocyte hypertrophy in chronic heart failure by activating the Rho protein/Rho-associated coiledcoil forming protein kinase signaling pathway.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Apoptosis; Cardiomegaly; Cell Survival; Dise | 2019 |
Hydroxyfasudil alleviates demyelination through the inhibition of MOG antibody and microglia activation in cuprizone mouse model.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Behavior, Animal; Brain; CD4-Positive T-Lymp | 2019 |
Inhibition of ROCK activity regulates the balance of Th1, Th17 and Treg cells in myasthenia gravis.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cells, Cultured; Disease Models, Animal; Fem | 2019 |
Systemic Rho-kinase inhibition using fasudil in mice with oxygen-induced retinopathy.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Animals, Newborn; Disease Models, Animal; Ma | 2019 |
CAR, a Homing Peptide, Prolongs Pulmonary Preferential Vasodilation by Increasing Pulmonary Retention and Reducing Systemic Absorption of Liposomal Fasudil.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Disease Models, Animal; Half-Life; Heparitin | 2019 |
Fasudil or genetic depletion of ROCK1 or ROCK2 induces anxiety-like behaviors.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Anxiety; Disease Models, Animal; Female; Mal | 2019 |
Intravitreal administration of HA-1077, a ROCK inhibitor, improves retinal function in a mouse model of huntington disease.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Disease Models, Animal; Electroretinography; | 2013 |
Protective effects of fasudil hydrochloride post-conditioning on acute myocardial ischemia/reperfusion injury in rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Apoptosis; bcl-2-Associated X Protein; Caspa | 2013 |
Rho-kinase inhibition prevents the progression of diabetic nephropathy by downregulating hypoxia-inducible factor 1α.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Albuminuria; Animals; Diabetes Mellitus, Type 2; Diab | 2013 |
Effects of a Rho kinase inhibitor on the sequential expression of ICAM-1, HIF-1α, Bcl-2 and caspase-3 in the retina of rats with oxygen-induced retinopathy.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Caspase 3; Disease Models, Animal; Gene Expr | 2013 |
Fasudil, a rho kinase inhibitor, limits motor neuron loss in experimental models of amyotrophic lateral sclerosis.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amyotrophic Lateral Sclerosis; Animals; Disease Model | 2013 |
Functional deterioration of endothelial nitric oxide synthase after focal cerebral ischemia.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blotting, Western; Disease Models, Animal; E | 2013 |
Inhibition of Rho-kinase alleviates peritoneal fibrosis and angiogenesis in a rat model of peritoneal dialysis.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Actins; Animals; Collagen Type I; Dialysis Solutions; | 2013 |
[Fasudil reverses monocrotaline-induced pulmonary hypertension in rats].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Disease Models, Animal; Familial Primary Pul | 2013 |
Long-term treatment with fasudil improves bleomycin-induced pulmonary fibrosis and pulmonary hypertension via inhibition of Smad2/3 phosphorylation.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Bleomycin; Disease Models, Animal; Humans; H | 2013 |
Rho kinase inhibition modulates microglia activation and improves survival in a model of amyotrophic lateral sclerosis.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amyotrophic Lateral Sclerosis; Animals; Astrocytes; A | 2014 |
Concurrent rho-kinase and tyrosine kinase platelet-derived growth factor inhibition in experimental pulmonary hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Becaplermin; Benzamides; Disease Models, Ani | 2014 |
The inhibition of Rho kinase blocks cell migration and accumulation possibly by challenging inflammatory cytokines and chemokines on astrocytes.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Animals, Newborn; Astrocytes; CD4-Positive T | 2014 |
Fasudil reversed MCT-induced and chronic hypoxia-induced pulmonary hypertension by attenuating oxidative stress and inhibiting the expression of Trx1 and HIF-1α.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Analysis of Variance; Animals; Disease Models, Animal | 2014 |
Rho kinase inhibition by fasudil in the striatal 6-hydroxydopamine lesion mouse model of Parkinson disease.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adrenergic Agents; Animals; Apomorphine; Corpus Stria | 2014 |
Long-term inhibition of Rho-kinase restores the LTP impaired in chronic forebrain ischemia rats by regulating GABAA and GABAB receptors.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain Ischemia; Chronic Disease; Disease Mod | 2014 |
Exceptional aggressiveness of cerebral cavernous malformation disease associated with PDCD10 mutations.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adolescent; Adult; Animals; Apoptosis Regulatory Prot | 2015 |
Priming Wharton's jelly-derived mesenchymal stromal/stem cells with ROCK inhibitor improves recovery in an intracerebral hemorrhage model.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blotting, Western; Cell Differentiation; Cel | 2015 |
[Expression of connexin43 in the myocardial hypertrophy of rats and intervention of fasudil].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cardiomyopathy, Hypertrophic; Connexin 43; D | 2014 |
Peptide-micelle hybrids containing fasudil for targeted delivery to the pulmonary arteries and arterioles to treat pulmonary arterial hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Administration, Inhalation; Animals; Antihypertensive | 2014 |
Combination of early constraint-induced movement therapy and fasudil enhances motor recovery after ischemic stroke in rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Analysis of Variance; Animals; Brain Infarction; Brai | 2016 |
Signaling Rho-kinase mediates inflammation and apoptosis in T cells and renal tubules in cisplatin nephrotoxicity.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Acute Kidney Injury; Amides; Animals; Anti-Inflammato | 2015 |
Fasudil prevents calcium oxalate crystal deposit and renal fibrogenesis in glyoxylate-induced nephrolithic mice.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Actins; Animals; Apoptosis; Cadherins; Calcium Oxalat | 2015 |
Multitarget intervention of Fasudil in the neuroprotection of dopaminergic neurons in MPTP-mouse model of Parkinson's disease.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Analysis of Variance; Animals; Cytokines; Disease Mod | 2015 |
Role of ROCK expression in gallbladder smooth muscle contraction.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Bile; Cholesterol; Disease Models, Animal; G | 2015 |
Neuroprotective effect of fasudil on inflammation through PI3K/Akt and Wnt/β-catenin dependent pathways in a mice model of Parkinson's disease.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals | 2015 |
Fasudil hydrochloride, a potent ROCK inhibitor, inhibits corneal neovascularization after alkali burns in mice.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Alkalies; Animals; Burns, Chemical; Corneal Neovascul | 2015 |
Fasudil, a clinically safe ROCK inhibitor, decreases disease burden in a Cbl/Cbl-b deficiency-driven murine model of myeloproliferative disorders.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adaptor Proteins, Signal Transducing; Animals; Diseas | 2016 |
Rho-kinase inhibitor fasudil reduces allergic airway inflammation and mucus hypersecretion by regulating STAT6 and NFκB.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Allergens; Animals; Asthma; Case-Control Studies; Cel | 2015 |
Fasudil, a Rho‑kinase inhibitor, prevents intima‑media thickening in a partially ligated carotid artery mouse model: Effects of fasudil in flow‑induced vascular remodeling.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Carotid Arteries; Carotid Intima-Media Thick | 2015 |
Effect of fasudil on hypoxic pulmonary hypertension and right ventricular hypertrophy in rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Disease Models, Animal; Heart; Hypertension, | 2015 |
Mechanisms of favorable effects of Rho kinase inhibition on myocardial remodeling and systolic function after experimental myocardial infarction in the rat.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Disease Models, Animal; Extracellular Signal | 2016 |
Inhibitory effects of fasudil on renal interstitial fibrosis induced by unilateral ureteral obstruction.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Actins; Animals; Cell Line; Cell Movement; Collagen T | 2015 |
Gabapentin Effects on PKC-ERK1/2 Signaling in the Spinal Cord of Rats with Formalin-Induced Visceral Inflammatory Pain.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amines; Animals; Behavior, Animal; Cell Membrane; Cyc | 2015 |
Fasudil, an inhibitor of Rho-associated coiled-coil kinase, attenuates hyperoxia-induced pulmonary fibrosis in neonatal rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Animals, Newborn; Blotting, Western; Disease | 2015 |
Changes of synapses in experimental autoimmune encephalomyelitis by using Fasudil.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blotting, Western; Cells, Cultured; Cytokine | 2016 |
Impacts of Rho kinase inhibitor Fasudil on Rho/ROCK signaling pathway in rabbits with optic nerve injury.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Disease Models, Animal; Female; Gene Express | 2015 |
RhoA/Rho-kinase activation promotes lung fibrosis in an animal model of systemic sclerosis.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Actins; Animals; Disease Models, Animal; Female; Hypo | 2016 |
Fasudil attenuates aggregation of α-synuclein in models of Parkinson's disease.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; alpha-Synuclein; Amides; Animals; Brain; Carrier Prot | 2016 |
Neuroprotection against cerebral ischemia/reperfusion injury by intravenous administration of liposomal fasudil.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Administration, Intravenous; Animals; Brain; Brain Is | 2016 |
Simultaneous Rho kinase inhibition in circulating leukocytes and in cardiovascular tissue in rats with high angiotensin converting enzyme levels.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Aorta; Disease Models, Animal; Gene Expressi | 2016 |
Fasudil treatment in adult reverses behavioural changes and brain ventricular enlargement in Oligophrenin-1 mouse model of intellectual disability.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Animals; Autism Spectrum Disorder; Behavior, A | 2016 |
Fasudil Enhances Therapeutic Efficacy of Neural Stem Cells in the Mouse Model of MPTP-Induced Parkinson's Disease.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals | 2017 |
Protective Effect of Inhaled Rho-Kinase Inhibitor on Lung Ischemia-Reperfusion Injury.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Administration, Inhalation; Animals; Biopsy, Needle; | 2017 |
Fasudil, an inhibitor of Rho-associated coiled-coil kinase, improves cognitive impairments induced by smoke exposure.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Apoptosis Regulatory Proteins; Behavior, Ani | 2016 |
RhoA Kinase Inhibition With Fasudil Versus Simvastatin in Murine Models of Cerebral Cavernous Malformations.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain Neoplasms; Disease Models, Animal; Fem | 2017 |
The ROCK Inhibitor Fasudil Prevents Chronic Restraint Stress-Induced Depressive-Like Behaviors and Dendritic Spine Loss in Rat Hippocampus.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Actin Depolymerizing Factors; Animals; Body Weight; D | 2017 |
The RhoA/ROCK Pathway Ameliorates Adhesion and Inflammatory Infiltration Induced by AGEs in Glomerular Endothelial Cells.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Animals; Cell Adhesion; Cell Movement; Cells, | 2017 |
Antiepileptic effects of two Rho-kinase inhibitors, Y-27632 and fasudil, in mice.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Animals; Anticonvulsants; Blotting, Western; | 2008 |
Activated RHOA and peripheral axon regeneration.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Axons; Axotomy; Cells, Cultured; Disease Mod | 2008 |
Neuroprotective potential of fasudil mesylate in brain ischemia-reperfusion injury of rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Calcium Channel Blockers; Cell Survival; Cer | 2009 |
The effect of the Rho-associated protein kinase inhibitor, HA-1077, in the rabbit ocular hypertension model induced by water loading.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Administration, Topical; Animals; Disease Models, Ani | 2009 |
Inhibition of Rho-dependent kinases ROCK I/II activates VEGF-driven retinal neovascularization and sprouting angiogenesis.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Angiogenesis Inducing Agents; Angiogenesis Inhibitors | 2009 |
Air pollution and cardiac remodeling: a role for RhoA/Rho-kinase.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Angiotensin II; Animals; Atmosphere Exposure Chambers | 2009 |
Vascular dysfunction in septic shock--any ROCKing news?
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Animals; Disease Models, Animal; Endothelium, | 2009 |
Effects of fasudil on early atherosclerotic plaque formation and established lesion progression in apolipoprotein E-knockout mice.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Apolipoproteins E; Atherosclerosis; Blood Pr | 2009 |
Amelioration of endothelial damage/dysfunction is a possible mechanism for the neuroprotective effects of Rho-kinase inhibitors against ischemic brain damage.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain; Brain Ischemia; Capillary Permeabilit | 2010 |
Effect of the rho-kinase inhibitor hydroxyfasudil on bladder overactivity: an experimental rat model.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Disease Models, Animal; Female; Rats; Rats, | 2009 |
Effects of rho-kinase inhibition on pulmonary hypertension, lung growth, and structure in neonatal rats chronically exposed to hypoxia.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Airway Remodeling; Amides; Animals; Animals, Newborn; | 2010 |
Fasudil, a Rho kinase inhibitor, drives mobilization of adult neural stem cells after hypoxia/reoxygenation injury in mice.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult Stem Cells; Animals; Antibodies; Astrocytes; Br | 2010 |
Involvement of Rho-kinase in collar-induced vasoconstriction and vascular hypersensitivity to serotonin in rat carotid.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Angiotensin II Type 1 Receptor Blockers; Animals; Car | 2011 |
Fasudil, a Rho-kinase inhibitor, attenuates induction and progression of cerebral aneurysms: experimental study in rats using vascular corrosion casts.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain; Cerebral Arteries; Disease Models, An | 2010 |
Therapeutic potential of experimental autoimmune encephalomyelitis by Fasudil, a Rho kinase inhibitor.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Analysis of Variance; Animals; Cell Proliferation; Ce | 2010 |
Modulation of cerebral malaria by fasudil and other immune-modifying compounds.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Curcumin; Disease Models, Animal; Enzyme Inh | 2010 |
Protective effects of cold spinoplegia with fasudil against ischemic spinal cord injury in rabbits.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Anterior Horn Cells; Aorta; Constriction; Di | 2010 |
Chronic treatment with an oral rho-kinase inhibitor restores erectile function by suppressing corporal apoptosis in diabetic rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Administration, Oral; Animals; Apoptosis; Blotting, W | 2011 |
Characterization of Fasudil in preclinical models of pain.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Analgesics; Animals; Disease Models, Animal; Male; Pa | 2010 |
Simvastatin improves clinical scores in a rabbit multiple infarct ischemic stroke model: synergism with a ROCK inhibitor but not the thrombolytic tissue plasminogen activator.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Anticholesteremic Agents; Brain Infarction; | 2010 |
NFATc3 contributes to intermittent hypoxia-induced arterial remodeling in mice.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Actins; Animals; Aorta, Thoracic; Bosentan; Dioxoles; | 2010 |
Effect of tongxinluo on vasoconstriction induced by the chronic injury of the adventitia in the rat carotid artery.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Carotid Arteries; Carotid Artery Diseases; C | 2010 |
Characterization of dysferlin deficient SJL/J mice to assess preclinical drug efficacy: fasudil exacerbates muscle disease phenotype.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Disease Models, Animal; Drug Evaluation, Pre | 2010 |
Rescue treatment with a Rho-kinase inhibitor normalizes right ventricular function and reverses remodeling in juvenile rats with chronic pulmonary hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Age Factors; Aging; Amides; Animals; Apoptosis; Cell | 2010 |
Optimisation of 6-substituted isoquinolin-1-amine based ROCK-I inhibitors.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amines; Animals; Disease Models, Animal; Hypertension | 2011 |
Rho-kinase inhibition ameliorates peritoneal fibrosis and angiogenesis in a rat model of peritoneal sclerosis.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Animals; Anti-Infective Agents, Local; Cells, | 2011 |
Preventive and therapeutic effects of the selective Rho-kinase inhibitor fasudil on experimental autoimmune neuritis.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Antigen-Presenting Cells; Carrier Proteins; | 2011 |
Inhalation of Stachybotrys chartarum evokes pulmonary arterial remodeling in mice, attenuated by Rho-kinase inhibitor.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cytokines; Disease Models, Animal; Lung; Lun | 2011 |
Involvement of subtypes γ and ε of protein kinase C in colon pain induced by formalin injection.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Analysis of Variance; Animals; Colonic Diseases; Dise | 2011 |
Rho kinase inhibition by fasudil exerts antioxidant effects in hypercholesterolemic rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Antioxidants; Cholesterol, Dietary; Disease | 2011 |
Pretreatment of Rho kinase inhibitor inhibits systemic inflammation and prevents endotoxin-induced acute lung injury in mice.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Acute Lung Injury; Animals; Disease Models, Animal; I | 2011 |
Wound contraction is attenuated by fasudil inhibition of Rho-associated kinase.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Animals; Biopsy, Needle; Blotting, Western; Ci | 2011 |
Increased expression of calcium/calmodulin-dependent protein kinase type II subunit δ after rat traumatic brain injury.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Apoptosis; Brain Injuries; Calcium Signaling | 2012 |
Changes in hippocampal synapses and learning-memory abilities in a streptozotocin-treated rat model and intervention by using fasudil hydrochloride.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Diabetes Mellitus, Experimental; Disease Mod | 2012 |
Antivasospastic effects of hydroxyfasudil, a Rho-kinase inhibitor, after subarachnoid hemorrhage.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blood Viscosity; Brain Ischemia; Disease Mod | 2012 |
Administration of fasudil, a ROCK inhibitor, attenuates disease in lupus-prone NZB/W F1 female mice.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Administration, Oral; Animals; Antigen-Antibody Compl | 2012 |
Fasudil improves survival and promotes skeletal muscle development in a mouse model of spinal muscular atrophy.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Anterior Horn Cells; Disease Models, Animal; | 2012 |
A Rho kinase (ROCK) inhibitor, fasudil, prevents matrix metalloproteinase-9-related hemorrhagic transformation in mice treated with tissue plasminogen activator.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blotting, Western; Cells, Cultured; Cerebral | 2012 |
Effect of fasudil, a selective inhibitor of Rho kinase activity, in the secondary injury associated with the experimental model of spinal cord trauma.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Disease Models, Animal; Male; Mice; Protein | 2012 |
Inhibition of rho kinase enhances survival of dopaminergic neurons and attenuates axonal loss in a mouse model of Parkinson's disease.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; 1-Methyl-4-phenylpyridinium; Animals; Axons; Behavior | 2012 |
Effect of chronic perinatal hypoxia on the role of rho-kinase in pulmonary artery contraction in newborn lambs.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Altitude; Animals; Animals, Newborn; Arterial Pressur | 2013 |
The Rho-kinase inhibitor fasudil restores normal motor nerve conduction velocity in diabetic rats by assuring the proper localization of adhesion-related molecules in myelinating Schwann cells.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; beta Catenin; Body Weight; Cadherins; Cateni | 2013 |
Effects of Rho-kinase inhibitor on vasopressin-induced chronic myocardial damage in rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cardiomyopathies; Chronic Disease; Disease M | 2002 |
Evidence for protein kinase C-mediated activation of Rho-kinase in a porcine model of coronary artery spasm.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blotting, Western; Calcium; Capillary Permea | 2003 |
Involvement of RhoA and possible neuroprotective effect of fasudil, a Rho kinase inhibitor, in NMDA-induced neurotoxicity in the rat retina.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cell Count; Disease Models, Animal; Drug Int | 2004 |
H-7 effect on outflow facility after trabecular obstruction following long-term echothiophate treatment in monkeys.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Accommodation, Ocular; Animals; Aqueous Humor; Cholin | 2004 |
Effects of topical H-7 on outflow facility, intraocular pressure, and corneal thickness in monkeys.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Administration, Topical; Animals; Aqueous Humor; Corn | 2004 |
Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Administration, Inhalation; Administration, Oral; Ami | 2005 |
Activation of Rho-associated kinase during augmented contraction of the basilar artery to serotonin after subarachnoid hemorrhage.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Basilar Artery; Disease Models, Animal; Enzy | 2005 |
Delayed treatment with Rho-kinase inhibitor does not enhance axonal regeneration or functional recovery after spinal cord injury in rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Behavior, Animal; Biotin; Dextrans; Disease | 2006 |
Protective effect of fasudil, a Rho-kinase inhibitor, on chemokine expression, leukocyte recruitment, and hepatocellular apoptosis in septic liver injury.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Animals; Apoptosis; Cell Communication; Chemo | 2006 |
Differential role of rho-kinase in pathological and physiological cardiac hypertrophy in rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adaptation, Physiological; Animals; Blood Pressure; C | 2006 |
The selective Rho-kinase inhibitor Fasudil is protective and therapeutic in experimental autoimmune encephalomyelitis.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Central Nervous System; Chemotaxis, Leukocyt | 2006 |
Chronic administration of an oral Rho kinase inhibitor prevents the development of vasculogenic erectile dysfunction in a rat model.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Disease Models, Animal; Dose-Response Relati | 2006 |
Long-term inhibition of Rho-kinase ameliorates hypoxia-induced pulmonary hypertension in mice.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Arterioles; Blotting, Western; Disease Model | 2006 |
The Rho-associated kinase inhibitor fasudil hydrochloride enhances neural regeneration after axotomy in the peripheral nervous system.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Axotomy; Disease Models, Animal; Male; Nerve | 2007 |
Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Disease Models, Animal; Disease Progression; | 2007 |
Improvement of cognitive deficit and neuronal damage in rats with chronic cerebral ischemia via relative long-term inhibition of rho-kinase.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain Infarction; Brain Ischemia; Cerebral C | 2008 |
Effects of combined therapy with a Rho-kinase inhibitor and prostacyclin on monocrotaline-induced pulmonary hypertension in rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Disease Models, Animal; Drug Interactions; D | 2007 |
Rho kinase inhibitor improves motor dysfunction and hypoalgesia in a rat model of lumbar spinal canal stenosis.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Anterior Horn Cells; Axons; Behavior, Animal | 2007 |
[Effects of fasudil on neuropathic pain-like state in mice].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Disease Models, Animal; Injections, Epidural | 2007 |
Defective endothelial nitric oxide synthase signaling is mediated by rho-kinase activation in rats with secondary biliary cirrhosis.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Actins; Animals; Aorta; Disease Models, Animal; Hemod | 2008 |
Wide therapeutic time window for Rho-kinase inhibition therapy in ischemic brain damage in a rat cerebral thrombosis model.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Antipyrine; Blood Flow Velocity; Brain Ische | 2008 |
Long-term inhibition of Rho-kinase ameliorates diastolic heart failure in hypertensive rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blotting, Western; Disease Models, Animal; D | 2008 |
Administration of the Rho-kinase inhibitor fasudil before ischemia or just after reperfusion, but not 30 min after reperfusion, protects the stunned myocardium in swine.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cardiotonic Agents; Disease Models, Animal; | 2008 |
AT-877, a Ca2+ antagonist, fails to reduce infarct size following rat middle-cerebral artery occlusion.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blood Glucose; Blood Pressure; Brain Ischemi | 1993 |
Lipopolysaccharide alters suckling rat liver glycogenolysis.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Animals, Newborn; Cytarabine; Disease Models | 1993 |
Role of protein kinase C in cisplatin nephrotoxicity.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Antineoplastic Agents; Cisplatin; Disease Mo | 1999 |
A new model of cerebral microthrombosis in rats and the neuroprotective effect of a Rho-kinase inhibitor.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain Infarction; Carotid Artery, Internal; | 2000 |
Antiischemic properties of fasudil in experimental models of vasospastic angina.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Angina Pectoris; Animals; Coronary Vasospasm; Disease | 2001 |
Possible prophylactic potential of HA1077, a Ca2+ channel antagonist and vasodilator, on chronic cerebral vasospasm.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Basilar Artery; Calcium; Cerebrovascular Cir | 1992 |
Inhibition of induced acute lung edema by a novel protein kinase C inhibitor.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Albumins; Animals; Disease Models, Animal; Enzyme Act | 1987 |